Pathophysiology of ANCA-associated small vessel vasculitis

被引:73
作者
Kallenberg C.G.M. [1 ]
机构
[1] Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, AA21, Hanzeplein 1, Groningen
关键词
ANCA; ANCA-associated vasculitis; Animal models; Antineutrophil cytoplasmic autoantibodies; Churg-Strauss syndrome; FimH; hLAMP-2; autoantibodies; Microscopic polyangiitis; MPO-ANCA; Myeloperoxidase; Necrotizing crescentic glomerulonephritis; PR3-ANCA; Proteinase; 3; Staphylococcus aureus; T-regulatory cells; Th17; cells; Wegener's granulomatosis;
D O I
10.1007/s11926-010-0138-6
中图分类号
学科分类号
摘要
Antineutrophil cytoplasmic autoantibodies (ANCAs) directed to proteinase 3 (PR3-ANCA) or myeloperoxidase (MPO-ANCA) are strongly associated with the ANCA-associated vasculitides-Wegener's granulomatosis, microscopic polyangiitis, and Churg-Strauss syndrome. Clinical observations, including the efficacy of B-cell depletion via rituximab treatment, support-but do not prove-a pathogenic role for ANCA in the ANCA-associated vasculitides. In vitro experimental studies show that the interplay of ANCA, neutrophils, the alternative pathway of the complement system, and endothelial cells could result in lysis of the endothelium. A pathogenic role for MPO-ANCA is strongly supported by in vivo experimental studies in mice and rats, which also elucidate the pathogenic mechanisms involved in lesion development. Unfortunately, an animal model for PR3-ANCA-associated Wegener's granulomatosis is not yet available. Here, cellular immunity appears to play a major role as well, particularly via interleukin-17-producing T cells, in line with granulomatous inflammation in the lesions. Finally, microbial factors, in particular Staphylococcus aureus and gram-negative bacteria, seem to be involved in disease induction and expression, but further studies are needed to define their precise role in disease development. © 2010 The Author(s).
引用
收藏
页码:399 / 405
页数:6
相关论文
共 48 条
[1]  
Kallenberg C.G.M., Heeringa P., Stegeman C.A., Mechanisms of disease: Pathogenesis and treatment of ANCA-associated vasculitides, Nature Clinical Practice Rheumatology, 2, 12, pp. 661-670, (2006)
[2]  
Kallenberg C.G.M., Churg-Strauss syndrome: Just one disease entity?, Arthritis and Rheumatism, 52, 9, pp. 2589-2593, (2005)
[3]  
Boomsma M.M., Stegeman C.A., Van Der Leij M.J., Et al., Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study, Arthritis Rheum, 43, pp. 2025-2033, (2000)
[4]  
Finkielman J.D., Merkel P.A., Schroeder D., Et al., Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis, Ann Intern Med, 147, pp. 611-619, (2007)
[5]  
Etanercept plus standard therapy for Wegener's granulomatosis, N Engl J Med, 352, pp. 351-361, (2005)
[6]  
Stegeman C.A., Cohen Tervaert J.W., Sluiter W.J., Et al., Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's granulomatosis, Ann Intern Med, 120, pp. 12-17, (1994)
[7]  
Sanders J.-S.F., Slot M.C., Stegeman C.A., Jayne D., Rasmussen N., Maintenance Therapy for Vasculitis Associated with Antineutrophil Cytoplasmic Autoantibodies [3] (multiple letters), New England Journal of Medicine, 349, 21, pp. 2072-2073, (2003)
[8]  
Stone J.H., Merkel P.A., Spiera R., Et al., Rituximab versus cyclophosphamide for ANCA-associated vasculitis, N Engl J Med, 363, pp. 221-232, (2010)
[9]  
Jones R.B., Cohen Tervaert J.W., Hauser T., Et al., Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis, N Engl J Med, 363, pp. 211-220, (2010)
[10]  
Bansal P.J., Tobin M.C., Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement, Ann Allergy Asthma Immunol, 93, pp. 398-401, (2004)